Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The 3 CHARM studies (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) and their combined results were presented at the ESC meeting and published in Lancet in September.

Late-Breaking Trials from the European Society of Cardiology Congress in Vienna, Austria: CHARM